Jul 2026· Metabolism: Clinical and Experimental· Vol 183, pp.
156692
· 0 citations· 59 references
Medicine
TL;DR
Individuals with MASLD who experience a CVD event have a higher subsequent risk of long-term LREs, and the value of targeted liver monitoring for high-risk individuals after CVD and integrated heart-liver co-management is underscored.
Abstract
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a risk factor for cardiovascular disease (CVD). However, the risk of liver-related events (LREs) after CVD is often overlooked. We investigated the association between incident CVD and subsequent long-term LRE risk among individuals with MASLD.
Methods
We used UK Biobank data to examine whether incident CVD (coronary heart disease [CHD], myocardial infarction [MI], heart failure [HF], or atrial fibrillation [AF]) was associated with subsequent long-term LREs (cirrhosis, decompensation, hepatocellular carcinoma, or liver-related death) in MASLD. Semi-Markov multi-state and time-dependent Cox regression models estimated transition rates and adjusted hazard ratios (aHRs). Imaging and proteomic data explored biological mechanisms.
Results
Among 142,454 individuals with MASLD, 22,630 (15.9%) developed incident CVD, and 2635 (1.8%) developed subsequent LREs over a median of 15.1 years. The transition rate from CVD to LREs was higher than the direct progression from MASLD to LREs (3.56 vs. 1.08 per 1000 person-years). Time-dependent Cox regression showed that incident CVD was associated with a higher risk of subsequent LREs (aHR 1.93, 95%CI 1.73-2.14). The risk varied by CVD subtypes, with HF highest, followed by AF, CHD, and MI (all P < 0.001). Exploratory integrated multi-omics analyses revealed associations between cardiac dysfunction and hepatic parameters, and identified a shared proteomic signature enriched in immune and fibrotic pathways.
Conclusions
Individuals with MASLD who experience a CVD event have a higher subsequent risk of long-term LREs. These findings underscore the value of targeted liver monitoring for high-risk individuals after CVD and integrated heart-liver co-management.
Background: Atherosclerotic cardiovascular disease (ASCVD) is a major cause of morbidity and mortality in metabolic dysfunction–associated steatotic liver disease (MASLD). We investigated whether fibrosis severity assessed using guideline-recommended noninvasive liver fibrosis pathways was associated with incident ASCV...
Jaehong Jeong, J. Hong, Dong Yun Kim et al.· Hepatology Communications· 0 citations
The results support the potential value of integrating MASLD screening into early CKM syndrome risk stratification and management and support the potential value of integrating insulin resistance and inflammation in early CKM syndrome risk stratification and management.
Zhuo-Xing Li, Qianyu Yang, Li Zang et al.· Diabetes Research and Clinic...· 0 citations
Cardiovascular-kidney-metabolic (CKM) syndrome integrates metabolic abnormalities, chronic kidney disease, and cardiovascular disease (CVD), with stages 0–3 representing a critical window for primary prevention. Whether the Chinese visceral adiposity index (CVAI) adds predictive value for CVD in this population r...
Long Feng, Geng Yang, He-Song Zeng et al.· Cardiovascular Diabetology· 0 citations
KM stages were associated with a stepwise increase in risk of CVD and all-cause mortality, with important sex-specific differences observed particularly for all-cause mortality, and support the relevance of CKM staging for cardiovascular risk stratification and prevention in the general population.
N. Ahanchi, R. de la Harpe, B. Delabays et al.· European Journal of Preventi...· 1 citation
Higher LE8 scores were associated with lower risks of MACE and CKD in ASCVD patients, and high LE8 achievement may attenuate risks toward non-ASCVD levels.
BACKGROUND
While metabolic dysfunction-associated steatotic liver disease (MASLD) has been consistently associated with increased cardiovascular risk in the general population, its association with cardiovascular disease (CVD) mortality in adults with established cardiometabolic risk factor (including obesity, hyperten...
Ruoting Wang, Wenli Li, J. Lazarus et al.· Cardiovascular Diabetology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.